KY 05009 |
| カタログ番号GC46015 |
KY 05009 は、ATP 競合性 Traf2 および Nck 相互作用キナーゼ (TNIK) 阻害剤であり、Ki は 100 nM です。 KY 05009 は、ヒト肺腺癌細胞における TGF-β1 誘導性の上皮間葉転換 (EMT) を薬理学的に阻害します。 KY 05009 は、TNIK のタンパク質発現と Wnt 標的遺伝子の転写活性を阻害し、がん細胞のアポトーシスを誘導します。 KY 05009 は抗がん作用を発揮します。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1228280-29-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
KY 05009 is an inhibitor of TRAF2- and NCK-interacting kinase (TNIK; Ki = 100 nM).1 It inhibits TGF-β1-induced Wnt, NF-κB, ERK, and JNK signaling and prevents TGF-β1-induced epithelial-to-mesenchymal transition (EMT) in A549 lung cancer cells without inducing cytotoxicity when used at a concentration of 10 μM. KY 05009 inhibits TNF-β1-induced A549 cell migration. It also induces apoptosis in RPMI-8226 multiple myeloma cells in a concentration-dependent manner.2
|1. Kim, J., Moon, S.H., Kim, B.T., et al. A novel aminothiazole KY-05009 with potential to inhibit Traf2- and Nck-interacting kinase (TNIK) attenuates TGF-β1-mediated epithelial-to-mesenchymal transition in human lung adenocarcinoma A549 cells. PLoS One 9(10), e110180 (2014).|2. Lee, Y., Jung, J.I., Park, K.Y., et al. Synergistic inhibition effect of TNIK inhibitor KY-05009 and receptor tyrosine kinase inhibitor dovitinib on IL-6-induced proliferation and Wnt signaling pathway in human multiple myeloma cells. Oncotarget 8(25), 41091-41101 (2017).
Average Rating: 5 (Based on Reviews and 34 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *